Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-PD-L1/TGFbetaRII fusion protein 6MW3511

A bifunctional fusion protein composed of a humanized anti-programmed death ligand 1 (PD-L1) nanobody fused to a mutant form of the human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration of anti-PD-L1/TGFbetaRII fusion protein 6MW3511, the TGFbetaRII moiety targets, binds to and neutralizes TGFbeta while the anti-PD-L1 nanobody moiety simultaneously targets, binds to, and inhibits the activity of PD-L1 on the tumor cell. This prevents both TGFbeta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores and enhances anti-tumor immune responses and inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers and play key roles in tumor immune suppression; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis. The TGFbetaRII moiety is modified to enhance the stability of the agent.
Synonym:anti-PD-L1 nanobody/TGFbetaRII mutant fusion protein 6MW3511
anti-PD-L1/TGFbetaRII bifunctional fusion protein 6MW3511
Code name:6MW3511
Search NCI's Drug Dictionary